CYTO (Altamira Therapeutics Ltd) יחס שווי שוק לשווי בספרים

Altamira Therapeutics is developing the innovative OligoPhore system for targeted RNA transport within tumors. Simultaneously, the company is creating inhalation therapies for pulmonary pathologies. The ratio of the company's market capitalization to its book value in the GURU.Markets chart shows that this metric equals 0.13. High confidence among B2B partners in the quality of the CYTO brand serves as a positive driver for long-term growth.

This indicator compares the market value of shares with net assets to identify whether a business is overvalued or undervalued. The metric determines the premium the market is willing to pay for future growth relative to current capital. Analyzing the market value-to-book value ratio helps avoid purchasing overheated assets. For Altamira Therapeutics (CYTO), this gap reflects the value of intellectual capital. Investors are pricing in the potential of patents and the unique expertise of molecular scientists.